Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ardelyx, a biopharmaceutical company, announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.
Ardelyx is focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs. Interested parties can access the live webcast of the presentation on the Ardelyx website. A replay will be available for 30 days post-event.
Ardelyx, un'azienda biofarmaceutica, ha annunciato che il suo Presidente e CEO, Mike Raab, presenterà al 43° Annuale J.P. Morgan Healthcare Conference. La presentazione è programmata per mercoledì 15 gennaio 2025 alle 16:30 PT a San Francisco.
Ardelyx si concentra sulla scoperta, sviluppo e commercializzazione di medicinali innovativi di prima classe per affrontare importanti esigenze mediche insoddisfatte. Le parti interessate possono accedere alla trasmissione in diretta della presentazione sul sito web di Ardelyx. Una registrazione sarà disponibile per 30 giorni dopo l'evento.
Ardelyx, una compañía biofarmacéutica, anunció que su Presidente y CEO, Mike Raab, presentará en la 43.ª Conferencia Anual de Salud J.P. Morgan. La presentación está programada para miércoles, 15 de enero de 2025 a las 4:30 p.m. PT en San Francisco.
Ardelyx se enfoca en descubrir, desarrollar y comercializar medicamentos innovadores de primera clase para abordar necesidades médicas importantes no satisfechas. Las partes interesadas pueden acceder a la transmisión en vivo de la presentación en el sitio web de Ardelyx. Una repetición estará disponible durante 30 días después del evento.
Ardelyx, 생명 공학 회사,가 Mike Raab 사장 겸 CEO가 제43회 J.P. Morgan Healthcare Conference에서 발표할 것이라고 발표했습니다. 발표는 2025년 1월 15일 수요일 오후 4:30 PT에 샌프란시스코에서 예정되어 있습니다.
Ardelyx는 중요한 의료적 필요를 충족하기 위해 혁신적이고 첫 번째 클래스의 약물을 발견, 개발 및 상용화하는 데 집중하고 있습니다. 관심 있는 분들은 Ardelyx 웹사이트에서 발표의 실시간 웹캐스트를 이용할 수 있습니다. 이벤트 후 30일 동안 다시 볼 수 있습니다.
Ardelyx, une entreprise biopharmaceutique, a annoncé que son Président et CEO, Mike Raab, présentera lors de la 43e Conférence Annuelle J.P. Morgan Healthcare. La présentation est prévue pour le mercredi 15 janvier 2025 à 16h30 PT à San Francisco.
Ardelyx se concentre sur la découverte, le développement et la commercialisation de médicaments innovants de première classe pour répondre à des besoins médicaux significatifs non satisfaits. Les parties intéressées peuvent accéder à la diffusion en direct de la présentation sur le site web d'Ardelyx. Un replay sera disponible pendant 30 jours après l'événement.
Ardelyx, ein biopharmazeutisches Unternehmen, hat bekannt gegeben, dass sein Präsident und CEO, Mike Raab, auf der 43. J.P. Morgan Healthcare Conference präsentieren wird. Die Präsentation ist für Mittwoch, den 15. Januar 2025 um 16:30 Uhr PT in San Francisco angesetzt.
Ardelyx konzentriert sich darauf, innovative, erstklassige Medikamente zu entdecken, zu entwickeln und zu vermarkten, um bedeutende unbefriedigte medizinische Bedürfnisse zu adressieren. Interessierte können die Live-Übertragung der Präsentation auf der Website von Ardelyx verfolgen. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
What date and time is the ARDX presentation at the J.P. Morgan Healthcare Conference?
Where can I watch the ARDX presentation at the J.P. Morgan Healthcare Conference?
How long will the ARDX presentation replay be available?
Who will present for ARDX at the J.P. Morgan Healthcare Conference?
What is the focus of Ardelyx as a biopharmaceutical company?
